full spectrum cell analysis®
eBioscience®

Anti-Mouse CD262 (DR5) Functional Grade Purified

Catalog Number: 16-5883
Also Known As:TRAIL-R2, TRAILR2, TNFRSF10B
RUO: For Research Use Only



Staining of DR5 transfected cells with Anti-Mouse CD262 (DR5) PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.

Product Information

Contents: Anti-Mouse CD262 (DR5) Functional Grade Purified
REF **Catalog Number:** 16-5883
Clone: MD5-1
Concentration: 1 mg/ml
Host/Isotype: Armenian Hamster IgG
Handling Conditions: Use in sterile environment.
Endotoxin Level: Less than 0.001 ng/ug antibody, as determined by the LAL assay.

Formulation: aqueous buffer, no sodium azide
Temperature Limitation: Store at 2-8°C.
LOT **Batch Code:** Refer to Vial
Use By: Refer to Vial

Description

The MD5-1 monoclonal antibody reacts with mouse DR5, also known as TRAIL-R2, Apo2, TRICK2, and KILLER. DR5 binds to TRAIL, activates NF-κB, and induces TRAIL-mediated apoptosis. DR5 mRNA is expressed broadly by normal tissue and human antigen is also expressed by some tumor cell lines.

Applications Reported

The MD5-1 antibody has been reported for use in flow cytometric analysis. It has also been reported for use in functional assays.

Applications Tested

The MD5-1 antibody has been tested by flow cytometric analysis of mouse DR5-transfected cells. This can be used at less than or equal to 0.25 µg per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.

References

Sheridan, J. P., S. A. Marster, R. M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C. L. Gray, K. Baker, W. I. Wood, A. D. Goddard, P. Godowski, A. Ashkenazi. 1997. Control of TRAIL-Induced Apoptosis by a Family of Signaling and Decoy Receptors. Science 277:818-821.
Takeda K, Yamaguchi N, Akiba H, Kojima Y, Hayakawa Y, Tanner JE, Sayers TJ, Seki N, Okumura K, Yagita H, Smyth MJ. 2004. Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy. J Exp Med. Feb 16;199(4):437-48. Epub 2004 Feb 09.

Related Products

14-6019 Anti-Human CD262 (TRAIL-R2) Purified (Polyclonal)
16-4888 Armenian Hamster IgG Isotype Control Functional Grade Purified (eBio299Arm)

Tel: 888.999.1371 or 858.642.2058 • Fax: 858.642.2046 • www.eBioscience.com • info@eBioscience.com